Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors

• DOI: 10.1200/jco.23.02233
• Publication Date: 2024-07-02T20:00:56Z
• Authors: Andrea B. Apolo; Daniel M. Girardi; Scot A. Niglio; Rosa Nadal; Andre R. Kydd; Nicholas Simon; Lisa Ley; Lisa M. Cordes; Elias Chandran; Seth M. Steinberg; Sunmin Lee; Min-Jung Lee; Shraddha Rastogi; Nahoko Sato; Liang Cao; A. Rouf Banday; Salah Boudjadi; Maria J. Merino; Antoun Toubaji; Dilara Akbulut; Bernadette Redd; Hadi Bagheri; Rene Costello; Sandeep Gurram; Piyush K. Agarwal; Heather J. Chalfin; Vladimir Valera; Howard Streicher; John Joseph Wright; Elad Sharon; William D. Figg; Howard L. Parnes; James L. Gulley; Biren Saraiya; Sumanta K. Pal; David Quinn; Mark N. Stein; Primo N. Lara; Donald P. Bottaro; Amir Mortazavi
• Keywords: Cabozantinib; Metastatic Urothelial Carcinoma

Cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) have shown promising efficacy safety in patients metastatic urothelial carcinoma (mUC), renal cell (mRCC), rare genitourinary (GU) tumors a dose-escalation phase I study. We report the final data analysis of safety, overall response rate (ORR), progression-free survival (PFS), (OS) seven expansion cohorts.